GAITHERBURG, Md. - An FDA advisory committee on Friday solidly endorsed Protein Design Labs Inc.'s Zenapax for the prevention of acute rejection of kidney transplants.

In addition to unanimous 12-0 votes asserting their confidence in the safety and efficacy of Zenapax for the kidney transplant indication, the Biological Response Modifiers Advisory Committee sent a strong signal to FDA that Zenapax also should be granted approval for prevention of liver and heart transplant (see accompanying story, A3).